Cargando…
Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial
Despite significant advances in drug‐based and device‐based therapies, heart failure remains a major and growing public health problem associated with substantial disability, frequent hospitalizations, and high economic costs. Keeping patients well and out of the hospital has become a major focus of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497370/ https://www.ncbi.nlm.nih.gov/pubmed/34390219 http://dx.doi.org/10.1002/ehf2.13550 |
_version_ | 1784579946566385664 |
---|---|
author | Abraham, William T. Bensimhon, Daniel Pinney, Sean P. Feitell, Scott C. Peacock, W. Frank Amir, Offer Burkhoff, Daniel |
author_facet | Abraham, William T. Bensimhon, Daniel Pinney, Sean P. Feitell, Scott C. Peacock, W. Frank Amir, Offer Burkhoff, Daniel |
author_sort | Abraham, William T. |
collection | PubMed |
description | Despite significant advances in drug‐based and device‐based therapies, heart failure remains a major and growing public health problem associated with substantial disability, frequent hospitalizations, and high economic costs. Keeping patients well and out of the hospital has become a major focus of heart failure disease management. Achieving and maintaining such stability in heart failure patients requires a holistic approach, which includes at least the management of the underlying heart disease, the management of comorbidities and the social and psychological aspects of the disease, and the management of haemodynamic/fluid status. In this regard, accurate assessment of elevated ventricular filling pressures or volume overload, that is, haemodynamic or pulmonary congestion, respectively, before the onset of worsening heart failure symptoms represents an important management strategy. Unfortunately, conventional methods for assessing congestion, such as physical examination and monitoring of symptoms and daily weights, are insensitive markers of worsening heart failure. Assessment tools that directly measure congestion, accurately and in absolute terms, provide more actionable information that enables the application of treatment algorithms designed to restore patient stability, in a variety of clinical settings. Two such assessment tools, implantable haemodynamic monitors and remote dielectric sensing (ReDS), meet the prerequisites for useful heart failure management tools, by providing accurate, absolute, and actionable measures of congestion, to guide patient management. This review focuses on the use of such technologies, across the spectrum of heart failure treatment settings. Clinical data are presented that support the broad use of pulmonary artery pressure‐guided and/or ReDS‐guided heart failure management in heart failure patients with reduced and preserved left ventricular ejection fraction. |
format | Online Article Text |
id | pubmed-8497370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84973702021-10-12 Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial Abraham, William T. Bensimhon, Daniel Pinney, Sean P. Feitell, Scott C. Peacock, W. Frank Amir, Offer Burkhoff, Daniel ESC Heart Fail Reviews Despite significant advances in drug‐based and device‐based therapies, heart failure remains a major and growing public health problem associated with substantial disability, frequent hospitalizations, and high economic costs. Keeping patients well and out of the hospital has become a major focus of heart failure disease management. Achieving and maintaining such stability in heart failure patients requires a holistic approach, which includes at least the management of the underlying heart disease, the management of comorbidities and the social and psychological aspects of the disease, and the management of haemodynamic/fluid status. In this regard, accurate assessment of elevated ventricular filling pressures or volume overload, that is, haemodynamic or pulmonary congestion, respectively, before the onset of worsening heart failure symptoms represents an important management strategy. Unfortunately, conventional methods for assessing congestion, such as physical examination and monitoring of symptoms and daily weights, are insensitive markers of worsening heart failure. Assessment tools that directly measure congestion, accurately and in absolute terms, provide more actionable information that enables the application of treatment algorithms designed to restore patient stability, in a variety of clinical settings. Two such assessment tools, implantable haemodynamic monitors and remote dielectric sensing (ReDS), meet the prerequisites for useful heart failure management tools, by providing accurate, absolute, and actionable measures of congestion, to guide patient management. This review focuses on the use of such technologies, across the spectrum of heart failure treatment settings. Clinical data are presented that support the broad use of pulmonary artery pressure‐guided and/or ReDS‐guided heart failure management in heart failure patients with reduced and preserved left ventricular ejection fraction. John Wiley and Sons Inc. 2021-08-13 /pmc/articles/PMC8497370/ /pubmed/34390219 http://dx.doi.org/10.1002/ehf2.13550 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Abraham, William T. Bensimhon, Daniel Pinney, Sean P. Feitell, Scott C. Peacock, W. Frank Amir, Offer Burkhoff, Daniel Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial |
title | Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial |
title_full | Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial |
title_fullStr | Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial |
title_full_unstemmed | Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial |
title_short | Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial |
title_sort | patient monitoring across the spectrum of heart failure disease management 10 years after the champion trial |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497370/ https://www.ncbi.nlm.nih.gov/pubmed/34390219 http://dx.doi.org/10.1002/ehf2.13550 |
work_keys_str_mv | AT abrahamwilliamt patientmonitoringacrossthespectrumofheartfailurediseasemanagement10yearsafterthechampiontrial AT bensimhondaniel patientmonitoringacrossthespectrumofheartfailurediseasemanagement10yearsafterthechampiontrial AT pinneyseanp patientmonitoringacrossthespectrumofheartfailurediseasemanagement10yearsafterthechampiontrial AT feitellscottc patientmonitoringacrossthespectrumofheartfailurediseasemanagement10yearsafterthechampiontrial AT peacockwfrank patientmonitoringacrossthespectrumofheartfailurediseasemanagement10yearsafterthechampiontrial AT amiroffer patientmonitoringacrossthespectrumofheartfailurediseasemanagement10yearsafterthechampiontrial AT burkhoffdaniel patientmonitoringacrossthespectrumofheartfailurediseasemanagement10yearsafterthechampiontrial |